TABLE 2.
Diagnostic performance of the novel peptide mixtures and of ESAT-6 and CFP-10 alone and in combinations for the validation panela
| Antigen(s) | Recognition (no. responding/no. tested) | Sensitivity, % (95% CI) | Specificity, % (95% CI) |
|---|---|---|---|
| Rv2654 | 9/21 | 42 (22-64) | 100 (100-100) |
| Rv3873A | 8/21 | 38 (17-59) | 95 (87-104) |
| Rv3878B | 12/21 | 57 (36-78) | 100 (100-100) |
| Rv2654 + Rv3873A + Rv3878B | 12/21 | 57 (36-78) | 95 (87-104) |
| ESAT-6 | 18/21 | 86 (71-101) | 100 (100-100) |
| CFP-10 | 15/21 | 71 (52-91) | 100 (100-100) |
| ESAT-6 + CFP-10 | 18/21 | 86 (71-101) | 100 (100-100) |
| ESAT-6 + CFP-10 + Rv2654 + Rv3873A + Rv3878B | 19/21 | 90 (78-103) | 95 (87-104) |
a
See Table 1, footnotes a, b, and c.